Online Articles: Clinical and Laboratory ObservationsSequential Therapy of Inotuzumab Ozogamicin and Blinatumomab as a Bridge-to Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Primary Refractory Acute Lymphoblastic Leukemia: A Case ReportUchida, Eriko MD*; Kurata, Takashi MD, PhD*; Komori, Kazutoshi MD, PhD*; Kobayashi, Jun MSc†,‡; Kubota, Noriko PhD†,‡; Sakashita, Kazuo MD, PhD*,‡ Author Information Departments of *Pediatric Hematology/Oncology †Laboratory Medicine ‡Life Science Research Center, Nagano Children’s Hospital, Azumino, Nagano Prefecture, Japan Informed consent was obtained from the patient’s parents for the publication of this case report, and the publication of this case report was approved by the Ethics Committee of Nagano Children’s Hospital (No.K-02-13). Supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI grants number 20K08750 and Nagano Children’s Hospital Research Grant (2019-2020). The authors declare no conflict of interest. Reprints: Kazuo Sakashita, MD, PhD, Department of Pediatric Hematology/Oncology, Nagano Children’s Hospital, 3100 Toyoshina, Azumino 399-8288, Nagano Prefecture, Japan (e-mail: [email protected]). Journal of Pediatric Hematology/Oncology: November 2021 - Volume 43 - Issue 8 - p e1228-e1230 doi: 10.1097/MPH.0000000000002205 Buy Metrics Abstract For relapsed/refractory (r/r) acute lymphocytic leukemia (ALL), there is a clinical question on how to combine blinatumomab and inotuzumab ozogamicin (InO), which are newly emerging immunotherapeutic agents, with conventional treatment. We report the case of an 11-year-old boy with B-cell ALL, who had a failed primary treatment and achieved molecular complete remission treated with a sequence therapy of InO and blinatumomab. Later, hematopoietic stem cell transplantation could be performed without major complications. Our case may suggest that the sequence therapy of InO and blinatumomab as a bridge-to hematopoietic stem cell transplantation could be effective in the treatment of pediatric r/r ALL. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.